Just – Evotech Biologics and Sandoz Join Forces to Develop and Produce a Defined Portfolio of Biomolar Molecules
Just – e voechc biological digital available payments, future payments in 640m named additional payments with additional unadjusted payments in commercial production dependent on commercial production and using the S.POD option
The partnership seeks to disrupt the market for affordable and accessible high-quality drug biosimilars for patients worldwide.
The partnership is based on EVOTEC Biologics’ AI-driven, fully integrated technology platform and continuous manufacturing combined with Sandoz’s leading biosimilars pipeline and capabilities.
The partnership includes Sandoz’s option to leverage Evotech Biologics’ full technology stack, creating bios development and infrastructure at its fully-owned ‘S.POD’ facility.
Hamburg, Germany and Seattle, WA / ACCESSWIRE / May 9, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT), Main Level, ISIN: DE0005664809; (NASDAQ: EVO) and Sandoz AG, a division of Novartis (NASDAQ: NVS) announced today that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., has entered into a multi-year, long-term technology partnership with Sandoz for the rapid development and production of multiple biosimilars.
The partnership includes an option to exclusively license Just-Evotec Biologics’ proprietary technology to build a wholly-owned SPOD facility (from Just-Evotec Biologics’ state-of-the-art J.POD facilities). Under the agreement, Just-Evotech Biologics will receive double-digit-million upfront and future payments of US$640m based on successful development progress, as well as additional undisclosed payments based on commercial manufacturing progress and the exercise of the S.POD option. .
The collaboration sets high ambitions for Just – Evotec Biologics to achieve higher quality and lower cost by introducing data-driven, fully integrated design capabilities and continuous manufacturing technology (J.DESIGN). . Both parties are closely aligned in their efforts to improve access to medicines for patients around the world. Development of biosimilars will accelerate over the next 12-18 months with significant collaboration at Just – Evotec Biologics’ J.POD facilities.
In addition, this partnership will enable Sandoz to build on Just – Evotec Biologics’ proprietary J.DESIGN platform, process development and continuous manufacturing technology without exclusive licensing, and will be an example of building state-of-the-art technology. A wholly owned ‘S.POD’ facility by the end of this decade. To ensure industry-leading performance, the Ju-Evotech Biologics team will support the design, construction, onboarding and training of the Sandoz team, fully leveraging the technology’s potential to positively impact cost, speed and quality in the biosimilars sector.
J.DESIGN, Just – Evotec Biologics is a data-driven, highly automated end-to-end biologics technology platform, leveraging a series of innovative technologies including artificial intelligence, machine learning, intensive and continuous bioprocesses. The platform is designed to de-risk clinical development by providing flexible clinical and commercial manufacturing capabilities within the same J.POD facility and ultimately enabling cost-effective commercial delivery of biologics.
Dr. Matthias Evers, Chief Business Officer, Evotech, commented. “We are excited to leverage this partnership to make a significant impact for patients worldwide. With Sandoz’s leadership in biosimilar development and commercialization and our disruptive technology platform in biologics development and manufacturing, this partnership has the potential to change the paradigm of what it means to find life-saving medicines.”
Dr. Linda Zuckerman, Executive Vice President, Global Head of Biotherapeutics at Just – Evotec Biologics, added: “We are excited to build a highly collaborative partnership with a global leader in the field and are committed to supporting the team at Sandoz in the development and manufacturing of a broad biosimilar portfolio at our state-of-the-art JPOD site. This partnership fully supports our mission of providing global access to valuable biotherapeutics.”
Evotec will hold a conference call on Wednesday, May 10, 2023 to provide additional information regarding this partnership. The conference call will be conducted in English.
Conference call details
day – Wednesday, May 10, 2023
Time: 02:00 pm CEST (08.00 am EDT, 01.00 pm BST)
To join by phone, please register in advance at this link. You will then receive a confirmation email with specific dialing details such as phone number, access code and PIN to access the call.
A simultaneous slide presentation for telephone participants is available under this link.
You will find a link on our home page at www.evotec.com shortly before the event to join the audio webcast and access the presentation slides.
About Us – Evotech Biologics
Just – Evotec Biologics, wholly owned by Evotec SE, is an industrial biologics platform company that uses AI/ML technologies and world-leading molecular design, cell line development, process consolidation and continuous manufacturing strategies to advance biotherapeutics from discovery. Clinical steps to commercialization. The Justice-Evotech Biologics team combines deep industry experience in data, protein, process and manufacturing sciences, including automation, to overcome the scientific and economic hurdles associated with the development of protein therapeutics. Our focus is on accelerating and expanding access to biotherapeutics through scientific and technological innovation on behalf of our proprietary projects and partners. Learn more at www.just-evotecbiologics.com.
About EVOTEC SE
Evotec is a life sciences company with a unique business model that delivers on its mission to discover and develop the most effective therapies and make them accessible to patients. The company’s multimodality platform incorporates unique innovative technologies, data and science to discover, develop and manufacture first-in-class and best-in-class pharmaceutical products. Evotec uses this “data-driven R&D to treat Autobahn” for proprietary projects and a network of partners including all Top 20 Pharma and more than 800 biotechnology companies, academic institutions as well as other healthcare stakeholders. Evotec currently has strategic activities in underserved medical areas, such as neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create a world-leading co-ownership pipeline for innovative therapies and has established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec works with more than 4,500 highly qualified people worldwide. The company’s 17 sites offer highly integrated technologies and services and operate as complementary clusters of excellence. For more information please go to www.evotec.com And follow us on Twitter @Evotec And LinkedIn.
This announcement contains forward-looking statements regarding future events, including the offering and listing of Evotec’s securities. such as “expect”, “believe”, “could”, “estimate”, “expect”, “think”, “can”, “could”, “plan”, “potential”, “should”, “target”, “want” and Variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include estimates regarding Evotec’s revenues, Group EBITDA and non-affiliated R&D expenses. These forward-looking statements are based on information available, and are expected by Evotec at the time these statements are made and Assumptions. No assurance can be given that such forward-looking statements are accurate. These statements involve known and unknown risks and are based on numerous assumptions and assumptions, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Evotec’s control. Evotec disclaims any expectations of Evotec. DISCLAIMS ANY OBLIGATION OR DUTY TO PUBLICLY RELEASE ANY MODIFICATIONS OR UPDATES CONTAINED HEREIN TO REFLECT A CHANGE.
Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications, email@example.com
Hinnerk Rohwedder, Director of Global Corporate Communications, firstname.lastname@example.org
IR address of Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, email@example.com
Source: Evotec SE
Check out the source version at accesswire.com: